{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:47:18Z","timestamp":1789764438091,"version":"4.0.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.kint.2026.04.042","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:54:38Z","timestamp":1783418078000},"page":"799-803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A rationale for C5 inhibition in severe Shiga toxin\u2013producing Escherichia coli\u2013associated hemolytic uremic syndrome"],"prefix":"10.1016","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8615-6847","authenticated-orcid":false,"given":"Paula A.","family":"Coccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura F.","family":"Alconcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2026.04.042_bib1","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00431-015-2642-1","article-title":"Epidemiology of haemolytic uremic syndrome in children: data from the North Italian HUS network","volume":"175","author":"Ardissino","year":"2016","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.kint.2026.04.042_bib2","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMra2108739","article-title":"Shiga toxin producing Escherichia coli and the hemolytic uremic syndrome","volume":"389","author":"Freedman","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.04.042_bib3","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00467-018-3991-6","article-title":"Hyponatremia: a new predictor of mortality in patients with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome","volume":"33","author":"Alconcher","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2026.04.042_bib4","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s00467-020-04829-4","article-title":"Severely ill pediatric patients with Shiga toxin-associated hemolytic uremic syndrome (STEC - HUS) who suffered from multiple organ involvement in the early stage","volume":"36","author":"Luna","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2026.04.042_bib5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/microorganisms7010015","article-title":"Complement activation contributes to the pathophysiology of Shiga toxin-associated hemolytic uremic syndrome","volume":"7","author":"Buelli","year":"2019","journal-title":"Microorganisms"},{"key":"10.1016\/j.kint.2026.04.042_bib6","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/cei.12601","article-title":"Activation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome","volume":"181","author":"Ferraris","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.kint.2026.04.042_bib7","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.medj.2023.09.002","article-title":"Shiga toxin targets the podocyte causing hemolytic uremic syndrome through endothelial complement activation","volume":"4","author":"Bowen","year":"2023","journal-title":"Med"},{"key":"10.1016\/j.kint.2026.04.042_bib8","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s00467-023-06183-7","article-title":"Kidney sequelae in 281 Shiga toxin-producing Escherichia coli-hemolytic uremic syndrome patients after a median follow-up of 12 years","volume":"39","author":"Alconcher","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2026.04.042_bib9","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3389\/fmed.2020.00357","article-title":"Low C3 serum levels predict severe forms of STEC-HUS with neurologic involvement","volume":"7","author":"Netti","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.kint.2026.04.042_bib10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00467-019-04334-3","article-title":"C3 levels and acute outcomes in Shiga toxin-related hemolytic uremic syndrome","volume":"35","author":"Balestracci","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2026.04.042_bib11","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.04.042_bib12","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMc1100859","article-title":"Eculizumab in severe Shiga-toxin-associated HUS","volume":"364","author":"Lapeyraque","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.04.042_bib13","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1093\/ndt\/gfs394","article-title":"Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC HUS registry","volume":"27","author":"Kielstein","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.04.042_bib14","author":"Ives","year":"2024","journal-title":"Efficacy and safety of eculizumab in children with Shiga-toxin-producing Escherichia coli haemolytic uraemic syndrome: the ECUSTEC RCT"},{"key":"10.1016\/j.kint.2026.04.042_bib16","unstructured":"Early Treatment With the Monoclonal C5 Antibody Eculizumab in Pediatric Patients Affected by Shiga-toxin Related Hemolytic and Uremic Syndrome: A Phase III Prospective Randomized Controlled Therapeutic Trial Versus Placebo. ClinicalTrials.gov Identifier: NCT02205541. Updated May 4, 2026. Accessed July 16, 2026. https:\/\/clinicaltrials.gov\/study\/NCT02205541"},{"key":"10.1016\/j.kint.2026.04.042_bib15","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1681\/ASN.0000000000000182","article-title":"Efficacy and safety of eculizumab in pediatric patients affected by Shiga toxin-related hemolytic uremic syndrome: a randomized, placebo-controlled trial","volume":"34","author":"Garnier","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.04.042_bib17","unstructured":"Eculizumab in Shiga-Toxin producing E. coli Haemolytic Uraemic Syndrome (ECUSTEC): a randomised, double-blind, placebo-controlled trial. EudraCT number: 2016-000997-39. Updated November 25, 2021. Accessed July 30, 2026. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-000997-39\/results"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826005181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826005181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:31:01Z","timestamp":1789723861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253826005181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0085253826005181"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2026.04.042","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A rationale for C5 inhibition in severe Shiga toxin\u2013producing Escherichia coli\u2013associated hemolytic uremic syndrome","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.04.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.05.025","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.05.024","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society of Nephrology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}